194 institutions hold shares in TherapeuticsMD Inc. (TXMD), with 43.49M shares held by insiders accounting for 11.21% while institutional investors hold 60.88% of the company’s shares. The shares outstanding are 286.69M, and float is at 266.15M with Short Float at 21.63%. Institutions hold 54.05% of the Float.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The top institutional shareholder in the company is Blackrock Inc. with over 21.42 million shares valued at $25.92 million. The investor’s holdings represent 5.52% of the TXMD Shares outstanding. As of Dec 30, 2020, the second largest holder is Price (T.Rowe) Associates Inc with 18.87 million shares valued at $22.83 million to account for 4.87% of the shares outstanding. The other top investors are FMR, LLC which holds 14.12 million shares representing 3.64% and valued at over $17.08 million, while Vanguard Group, Inc. (The) holds 3.39% of the shares totaling 13.17 million with a market value of $15.93 million.
TherapeuticsMD Inc. (NASDAQ: TXMD) is 9.92% higher on its value in year-to-date trading and has touched a low of $0.85 and a high of $2.75 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The TXMD stock was last observed hovering at around $1.38 in the last trading session, with the day’s loss setting it -0.05% off its average median price target of $5.00 for the next 12 months. It is also 85.22% off the consensus price target high of $9.00 offered by 5 analysts, but current levels are 55.67% higher than the price target low of $3.00 for the same period.
Currently trading at $1.33, the stock is -9.17% and -17.65% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 6.75 million and changing -3.62% at the moment leaves the stock -10.82% off its SMA200. TXMD registered 23.15% gain for a year compared to 6-month gain of -5.67%. The firm has a 50-day simple moving average (SMA 50) of $1.6259 and a 200-day simple moving average (SMA200) of $1.4617.
The stock witnessed a -12.50% loss in the last 1 month and extending the period to 3 months gives it a 11.76%, and is -12.50% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.46% over the week and 10.18% over the month.
TherapeuticsMD Inc. (TXMD) has around 400 employees, a market worth around $530.75M and $64.90M in sales. Distance from 52-week low is 55.92% and -51.64% from its 52-week high. The company has generated returns on investments over the last 12 months (-136.80%).
TherapeuticsMD Inc. (TXMD) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for TherapeuticsMD Inc. (TXMD) is a “Buy”. 5 analysts offering their recommendations for the stock have an average rating of 1.70, where 0 rate it as a Hold and 0 think it is a “Overweight”. 5 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
TherapeuticsMD Inc. is expected to release its quarterly report on 05/04/2021 and quarterly earnings per share for the current quarter are estimated at -$0.1 with sales reaching $20.31M over the same period.The EPS is expected to grow by 6.90% this year, but quarterly earnings will post 68.40% year-over-year. Quarterly sales are estimated to grow 65.80% in year-over-year returns.
TherapeuticsMD Inc. (TXMD) Insider Activity
A total of 5 insider transactions have happened at TherapeuticsMD Inc. (TXMD) in the last six months, with sales accounting for 3 and purchases happening 2 times. The most recent transaction is an insider purchase by Finizio Robert G, the company’s CEO. SEC filings show that Finizio Robert G bought 46,000 shares of the company’s common stock on Jun 09 at a price of $1.44 per share for a total of $66360.0. Following the purchase, the insider now owns 18.4 million shares.
TherapeuticsMD Inc. disclosed in a document filed with the SEC on Jun 09 that Collins Cooper C. (Director) bought a total of 47,500 shares of the company’s common stock. The trade occurred on Jun 09 and was made at $1.45 per share for $68875.0. Following the transaction, the insider now directly holds 0.14 million shares of the TXMD stock.
Still, SEC filings show that on Jun 08, Collins Cooper C. (Director) acquired 26,500 shares at an average price of $1.45 for $38425.0. The insider now directly holds 92,500 shares of TherapeuticsMD Inc. (TXMD).
TherapeuticsMD Inc. (TXMD): Who are the competitors?
The company’s main competitors (and peers) include AbbVie Inc. (ABBV) that is trading 46.87% up over the past 12 months and Pfizer Inc. (PFE) that is 25.05% higher over the same period. Agile Therapeutics Inc. (AGRX) is -4.39% down on the 1-year trading charts. Short interest in the company’s stock has fallen -26.23% from the last report on Feb 11, 2021 to stand at a total of 72.67 million short shares sold with a short interest ratio of 3.13.